Pharming Group NV (PHAR) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the stock has some positive catalysts, such as the analyst's raised price target and positive trial results, the lack of strong trading signals, neutral technical indicators, and recent negative news regarding FDA issues make it prudent to hold off on investing for now.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 43.194, and moving averages are converging. The stock is trading near its pivot level of 16.346, with resistance at 17.178 and support at 15.513. No strong buy or sell signals are present.

Positive Catalysts

Guggenheim analyst raised the price target from $32 to $39, citing positive trial results for RAPIDe-3 and increased global peak sales estimates for deucrictibant.

Neutral/Negative Catalysts

Recent investigation by Pomerantz LLP for potential securities fraud following a significant stock drop due to FDA's Complete Response Letter regarding Joenja®. Neutral trading sentiment from hedge funds and insiders.

Financial Performance

No financial data available for analysis. Preliminary Q4 and full-year 2025 results will be released on March 12, 2026.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Guggenheim maintains a Buy rating with an increased price target of $39, citing strong trial results and higher sales estimates.

2 Analyst Rating

Wall Street analysts forecast PHAR stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 15.990

Low

Averages

39.5

High

Current: 15.990

Low

Averages

39.5

High

Guggenheim

Debjit Chattopadhyay

Buy

maintain

$32 -> $39

AI Analysis

2025-12-04

Reason

Guggenheim

Debjit Chattopadhyay

Price Target

$32 -> $39

AI Analysis

2025-12-04

maintain

Buy

Reason

Guggenheim analyst Debjit Chattopadhyay raised the firm's price target on Pharvaris to $39 from $32 and keeps a Buy rating on the shares after the company shared that its RAPIDe-3 trial hit on the primary and all 11 secondary endpoints. Post the RAPIDe-3 topline data readout, the firm is increasing its global peak sales estimate for deucrictibant to $1.65B from $1.4B during 2037.

Oppenheimer

Outperform

maintain

$41 -> $42

2025-11-07

Reason

Oppenheimer

Price Target

$41 -> $42

2025-11-07

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Pharming to $42 from $41 and keeps an Outperform rating on the shares. The firm notes the company reported strong Q3 results with $97M in sales, meaningfully above its estimates and generally in line with consensus of $90M/$98M, respectively.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PHAR

Unlock Now

PHAR Should I Buy

PHAR Should I Buy

Should You Buy Pharming Group NV (PHAR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch